Multiple Sclerosis

Purpose of Study:  This is a Phase II, randomized, open-label, three-arm study comparing low- and high-dose CAMPATH® and high-dose Rebif® in patients with early, active relapsing-remitting Multiple Sclerosis (MS) who have not been previously treated with immunotherapies other than steroids.

Inclusion Criteria:

• Be between the ages of 18 and 50
• Have experienced the onset of MS symptoms within the past three years
• Have had at least two clinical episodes of MS in the last two years

Exclusion Criteria:

• Untreated severe psychiatric disorder.
• Previous treatment with Campath
• Uncontrolled seizures

If you qualify, all study related care is provided at no charge including:

• Study Drug
• Study visits and study related procedures/tests
• Laboratory tests
• Financial compensation for time/travel expenses per study-required visit.

Inclusion/Exclusion Criteria Must Be Met